Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  IDEXX Laboratories, Inc.    IDXX

Delayed Quote. Delayed  - 05/27 09:59:58 pm
90.07 USD   +0.37%
05/19 IDEXX LABORATOR : Why Investors Still See Value in Alkermes, AMAG Ph..
04/29 IDEXX LABORATOR : beats Street 1Q forecasts
04/29 IDEXX LABORATOR : Announces First Quarter Results
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

IDEXX Laboratories : Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/19/2016 | 02:51pm CEST

NEW YORK, May 19, 2016 /PRNewswire/ --

The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:

http://www.activewallst.com

On Wednesday, Alkermes PLC's stock climbed 0.63%, to close the day at $40.23 with a total volume of 593,666 shares traded. The Company's shares have advanced 22.47% in the previous three months. The stock is trading 9.78% above its 50-day moving average. Additionally, shares of Alkermes have a Relative Strength Index (RSI) of 57.96. Sign up and activate your free alert on ALKS at:

http://www.activewallst.com

Shares in AMAG Pharmaceuticals Inc. saw a correction of 1.55%, finishing Wednesday's session at $18.46. The stock recorded a trading volume of 1.08 million shares. The Company's shares are trading below their 50-day moving average by 21.24%. Furthermore, AMAG Pharmaceuticals' stock has an RSI of 30.42. The complimentary trade alert on AMAG can be accessed at:

http://www.activewallst.com

IDEXX Laboratories Inc.'s stock finished 1.26% higher at $88.33 at yesterday's close. A total volume of 940,462 shares was traded, above their three months average volume of 688,200 shares. The Company's shares have advanced 9.97% in the past month, 25.06% over the previous three months, and 21.13% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.39% and 19.04%, respectively. Additionally, shares of IDEXX Laboratories have an RSI of 71.24. Register for free on ActiveWallSt.com and activate the trade alert on IDXX at:

http://www.activewallst.com

Shares in Atossa Genetics Inc. saw a correction of 6.04%, ending the session at $0.26. The stock recorded a trading volume of 313,863 shares. The Company's shares are trading 16.22% below their 50-day moving. Moreover, Atossa Genetics' stock has an RSI of 42.95. ATOS free trade alert is just a click away at:

http://www.activewallst.com

Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com

        
         
        CONTACT: 
        For any questions, inquiries, or comments reach out to us directly at: 
        Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom 
        Email: info@activewallst.com 
        Phone number:  1-858-257-3144 

 

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on IDEXX LABORATORIES, INC.
05/19 IDEXX LABORATORIES : Why Investors Still See Value in Alkermes, AMAG Pharmaceuti..
05/06 IDEXX LABORATORIES INC /DE : Submission of Matters to a Vote of Security Holders..
04/29 IDEXX LABORATORIES : DE Management's Discussion and Analysis of Financial Condit..
04/29 IDEXX LABORATORIES : beats Street 1Q forecasts
04/29 IDEXX LABORATORIES INC /DE : Results of Operations and Financial Condition, Fina..
04/29 IDEXX LABORATORIES : Announces First Quarter Results
04/26IDEXX LABORATORIES, INC. : quaterly earnings release
04/14 IDEXX LABORATORIES : to Release 2016 First Quarter Financial Results
04/12 IDEXX LABORATORIES : to Release 2016 First Quarter Financial Results
03/07 IDEXX LABORATORIES : Sources Sought Notice - SOLE SOURCE JUSTIFICATION
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials